These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 25856426)
1. Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. Kwon HJ; Xing W; Chan K; Niedziela-Majka A; Brendza KM; Kirschberg T; Kato D; Link JO; Cheng G; Liu X; Sakowicz R PLoS One; 2015; 10(4):e0122844. PubMed ID: 25856426 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983 [TBL] [Abstract][Full Text] [Related]
4. In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir. Cheng G; Tian Y; Doehle B; Peng B; Corsa A; Lee YJ; Gong R; Yu M; Han B; Xu S; Dvory-Sobol H; Perron M; Xu Y; Mo H; Pagratis N; Link JO; Delaney W Antimicrob Agents Chemother; 2016 Jan; 60(3):1847-1853. PubMed ID: 26824950 [TBL] [Abstract][Full Text] [Related]
5. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Lim PJ; Gallay PA Curr Opin Virol; 2014 Oct; 8():30-7. PubMed ID: 24879295 [TBL] [Abstract][Full Text] [Related]
10. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies. Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675 [TBL] [Abstract][Full Text] [Related]
11. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. Wyles D; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Martin R; Afdhal NH; Kowdley KV; Lawitz E; Brainard DM; Miller MD; Mo H; Gane EJ J Hepatol; 2017 Apr; 66(4):703-710. PubMed ID: 27923693 [TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899 [TBL] [Abstract][Full Text] [Related]
13. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir. Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932 [TBL] [Abstract][Full Text] [Related]
14. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems. Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461 [TBL] [Abstract][Full Text] [Related]
15. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Wyles D; Mangia A; Cheng W; Shafran S; Schwabe C; Ouyang W; Hedskog C; McNally J; Brainard DM; Doehle BP; Svarovskaia E; Miller MD; Mo H; Dvory-Sobol H Antivir Ther; 2018; 23(3):229-238. PubMed ID: 28650844 [TBL] [Abstract][Full Text] [Related]
16. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. Camus G; Han B; Asselah T; Hsieh D; Dvory-Sobol H; Lu J; Svarovskaia E; Martin R; Parhy B; Miller MD; Brainard DM; Kersey K; Abergel A; Mo H J Viral Hepat; 2018 Feb; 25(2):134-143. PubMed ID: 28984067 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777 [TBL] [Abstract][Full Text] [Related]
18. Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664 [TBL] [Abstract][Full Text] [Related]